Proficiency testing of immunohistochemical biomarker assays in breast cancer
- 29 October 2008
- journal article
- Published by Springer Nature in Virchows Archiv
- Vol. 453 (6) , 537-543
- https://doi.org/10.1007/s00428-008-0688-4
Abstract
Steroid hormone receptor expression and HER2 status have become an integral part of histopathologic characterization of breast cancer and corresponding biomarker assays have gained important prognostic and predictive impact. Because testing inaccuracy could provide a major hazard to modern breast cancer therapy, a laboratory proficiency testing program has been implemented in Germany using tissue microarrays (TMAs). In four consecutive annual trials with 142 laboratories participating on average per trial, estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (Her2) were determined immunohistochemically by participating laboratories followed by central review of all immunostains. Performance strongly depended on the ambiguity of expression of the target molecule in the test samples. In clearly positive (Allred score 7–8; Her2 3+) or negative tissue samples, the majority of participants (86%) achieved concordance rates exceeding 85%. By contrast, low expression of ER or PR (Allred score 3–4) as well as Her2 status 2+ led to considerable lower concordance rates ranging from 41% (Her2 2+) to 75% (PR). Poor reproducibility was predominantly due to inadequate laboratory performance whereas interobserver agreement (weighted kappa statistics) usually was high (>0.81). Laboratories that participated in more than one of the four subsequent trials (n = 110) showed a highly significant improvement of performance. In conclusion, a TMA-based proficiency testing of biomarkers in breast cancer has been implemented in Germany over a 5-year period and revealed reliable assessment of unambiguously positive and negative test samples. Low-expressing tumor samples with regard to steroid hormone receptor expression and Her2 status 2+ led to inaccurate evaluations by up to 59% of participants. Regularly participating laboratories showed a significant improvement of performance.Keywords
This publication has 18 references indexed in Scilit:
- Prognostic and Predictive Value of Centrally Reviewed Expression of Estrogen and Progesterone Receptors in a Randomized Trial Comparing Letrozole and Tamoxifen Adjuvant Therapy for Postmenopausal Early Breast Cancer: BIG 1-98Journal of Clinical Oncology, 2007
- Standardizing Slide-Based Assays in Breast Cancer: Hormone Receptors, HER2, and Sentinel Lymph NodesClinical Cancer Research, 2007
- American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast CancerJournal of Clinical Oncology, 2007
- Quantification of immunohistochemistry—issues concerning methods, utility and semiquantitative assessment IIHistopathology, 2006
- Meeting Highlights: International Expert Consensus on the Primary Therapy of Early Breast Cancer 2005Annals of Oncology, 2005
- Estrogen Receptor Analysis for Breast CancerAdvances in Anatomic Pathology, 2005
- Tissue Microarrays Are an Effective Quality Assurance Tool for Diagnostic ImmunohistochemistryLaboratory Investigation, 2002
- Tissue Array Technology for Testing Interlaboratory and Interobserver Reproducibility of Immunohistochemical Estrogen Receptor Analysis in a Large Multicenter TrialAmerican Journal of Clinical Pathology, 2002
- Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2New England Journal of Medicine, 2001
- Reliability of immunohistochemical demonstration of oestrogen receptors in routine practice: interlaboratory variance in the sensitivity of detection and evaluation of scoring systemsJournal of Clinical Pathology, 2000